Annovis to Host Year-End Investor Webcast on December 11, 2024
Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company focused on neurodegenerative diseases, announces an upcoming live investor webcast on December 11, 2024, at 4:30 PM EST. Dr. Maria Maccecchini, Founder, President, and CEO, will present comprehensive updates on the company's achievements and future plans.
The webcast will cover key topics including updates on Phase 3 studies for Parkinson's and Alzheimer's diseases, FDA interactions, financial health, and strategic initiatives for 2025. Participants can submit questions in advance to ir@annovisbio.com for the Q&A session following the presentation.
Annovis Bio (NYSE: ANVS), una società in fase clinica focalizzata sulle malattie neurodegenerative, annuncia un prossimo webcast dal vivo per gli investitori il 11 dicembre 2024, alle 16:30 EST. La Dott.ssa Maria Maccecchini, fondatrice, presidente e CEO, presenterà aggiornamenti esaustivi sui risultati e sui piani futuri della società.
Il webcast tratterà argomenti chiave, inclusi aggiornamenti sugli studi di fase 3 per il morbo di Parkinson e l'Alzheimer, interazioni con la FDA, salute finanziaria e iniziative strategiche per il 2025. I partecipanti possono inviare domande in anticipo all'indirizzo ir@annovisbio.com per la sessione di domande e risposte dopo la presentazione.
Annovis Bio (NYSE: ANVS), una compañía de plataforma de medicamentos en etapa clínica enfocada en enfermedades neurodegenerativas, anuncia una próxima webcast en vivo para inversores el 11 de diciembre de 2024, a las 4:30 PM EST. La Dra. Maria Maccecchini, fundadora, presidenta y CEO, presentará actualizaciones completas sobre los logros de la compañía y los planes futuros.
La webcast cubrirá temas clave, incluidos actualizaciones sobre los estudios de fase 3 para las enfermedades de Parkinson y Alzheimer, interacciones con la FDA, salud financiera e iniciativas estratégicas para 2025. Los participantes pueden enviar preguntas con antelación a ir@annovisbio.com para la sesión de preguntas y respuestas posterior a la presentación.
Annovis Bio (NYSE: ANVS), 신경퇴행성 질환에 집중하는 임상 단계의 의약품 플랫폼 회사가 2024년 12월 11일 오후 4:30 EST에 라이브 투자자 웹캐스트를 발표합니다. 마리아 마체키니 박사, 창립자이자 회장 및 CEO가 회사의 성과와 미래 계획에 대한 포괄적인 업데이트를 제공합니다.
웹캐스트에서는 파킨슨병과 알츠하이머병에 대한 3상 연구의 업데이트, FDA와의 상호작용, 재무 건강, 2025년 전략적 이니셔티브 등 주요 주제를 다룰 것입니다. 참가자는 발표 후 질의응답 세션을 위해 ir@annovisbio.com으로 미리 질문을 제출할 수 있습니다.
Annovis Bio (NYSE: ANVS), une entreprise de plateforme de médicaments en phase clinique axée sur les maladies neurodégénératives, annonce un prochain webinaire en direct pour les investisseurs le 11 décembre 2024 à 16h30 EST. Dr Maria Maccecchini, fondatrice, présidente et PDG, présentera des mises à jour complètes sur les réalisations et les projets futurs de l'entreprise.
Le webinaire couvrira des sujets clés, y compris des mises à jour sur les études de phase 3 pour les maladies de Parkinson et d'Alzheimer, les interactions avec la FDA, la santé financière et les initiatives stratégiques pour 2025. Les participants peuvent soumettre des questions à l'avance à ir@annovisbio.com pour la session de questions-réponses qui suivra la présentation.
Annovis Bio (NYSE: ANVS), ein Unternehmen in der klinischen Phase, das sich auf neurodegenerative Erkrankungen konzentriert, kündigt ein bevorstehendes Live-Webcast für Investoren am 11. Dezember 2024 um 16:30 Uhr EST an. Dr. Maria Maccecchini, Gründerin, Präsidentin und CEO, wird umfassende Neuigkeiten über die Erfolge des Unternehmens und die zukünftigen Pläne präsentieren.
Das Webcast wird wichtige Themen abdecken, einschließlich Updates zu Phase-3-Studien für Parkinson- und Alzheimer-Krankheiten, Interaktionen mit der FDA, finanzielle Gesundheit und strategische Initiativen für 2025. Teilnehmer können Fragen im Voraus an ir@annovisbio.com für die anschließende Q&A-Sitzung nach der Präsentation senden.
- None.
- None.
MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is pleased to announce a live investor webcast scheduled for December 11, 2024, at 4:30 PM EST.
Webcast Details:
- Date: December 11, 2024
- Time: 4:30 PM EST
- Registration Link: Register Here
Dr. Maria Maccecchini, Founder, President, and CEO of Annovis, will lead the webcast, providing a comprehensive update on the company's recent achievements, ongoing clinical programs, and strategic initiatives for 2025.
Key topics will include:
- Clinical Progress: Updates on Phase 3 studies for Parkinson's and Alzheimer's diseases.
- Regulatory Milestones: Insights into interactions with the U.S. Food and Drug Administration (FDA) and upcoming submissions.
- Financial Overview: Summary of the company's financial health and funding strategies.
- Strategic Outlook: Plans for advancing neurodegenerative disease therapies in the coming year.
Investors and interested parties are encouraged to register in advance through the provided Zoom link. To address the high volume of recent inquiries, Annovis will strive to answer as many questions as possible during the Q&A session following the presentation. Participants are invited to submit their questions in advance to ir@annovisbio.com.
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://www.annovisbio.com/email-alerts. Additionally, we invite you to explore our updated investor website, which provides comprehensive access to company news, financial reports, and other key information.
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company's plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap. Additional risk factors are detailed in the Company's periodic filings with the SEC, including those listed in the "Risk Factors" section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
www.annovisbio.com/investors-relations
IR@annovisbio.com
FAQ
When is Annovis Bio (ANVS) hosting their year-end investor webcast?
What clinical trials will be discussed during the Annovis Bio (ANVS) webcast?
How can investors participate in the Annovis Bio (ANVS) December 2024 webcast?
What topics will be covered in the Annovis Bio (ANVS) December 2024 investor webcast?
